Halozyme Therapeutics Hits New 52-Week High of $79.46, Up 51.62%

Halozyme Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 79.46 on September 23, 2025. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, where it has demonstrated a remarkable one-year performance of 51.62%, significantly outpacing the S&P 500's 17.38% return.
With a market capitalization of USD 8,872 million, Halozyme is classified as a small-cap company. The stock's price-to-earnings (P/E) ratio stands at 14.00, indicating a favorable valuation relative to its earnings. The company has shown impressive management efficiency, highlighted by a return on equity (ROE) of 167.48% and a robust return on capital employed (ROCE) of 59.50%.

Additionally, Halozyme has maintained a strong financial position, evidenced by a healthy EBIT to interest ratio of 23.90, and it has reported positive results for six consecutive quarters. The company's operating profit has grown at an annual rate of 73.99%, while net profit increased by 39.85%. With these strong fundamentals, Halozyme Therapeutics continues to solidify its position in the market.